Answers are grounded in this paper and cite their sources.
Background Radiation-induced skin injury (RISI) is a frequent and clinically relevant toxicity in breast cancer patients receiving tumor bed boost following breast-conserving surgery. Although boost irradiation improves local control, the associated increase in skin dose may adversely affect treatment tolerance and cosmetic outcomes. In real-world practice, the risk of RISI is determined by a combination of dosimetric and patient-related factors; however, pre-treatment, decision-oriented risk stratification remains limited. Methods This retrospective single-center study included 140 consecutive breast cancer patients treated with breast-conserving surgery and adjuvant radiotherapy between 2020 and 2025. Seventeen patients were excluded because of incomplete clinical or dosimetric records. Propensity score matching (1:1) was performed based on age, body mass index (BMI), and concurrent chemotherapy, yielding 58 matched pairs (N = 116). Acute RISI was graded according to the RTOG acute radiation morbidity scoring criteria, with Grade ≥2 defined as clinically significant toxicity. Multivariable logistic regression was used to identify independent risk factors. Model performance was assessed using receiver operating characteristic (ROC) analysis, calibration, and decision curve analysis (DCA). Results In the matched cohort, Grade ≥2 RISI occurred in 27 of 58 patients (46.6%) receiving tumor bed boost and in 20 of 58 patients (34.5%) without boost. Skin maximum dose (D max ) (OR, 1.11 per Gy; 95% CI, 1.01–1.21; P = .027) and concurrent chemotherapy (OR, 2.39; 95% CI, 1.06–5.39; P = .036) were independently associated with RISI. The model demonstrated moderate discriminative performance (AUC, 0.74; 95% CI, 0.66–0.82) with good calibration. DCA suggested a modest net benefit within a limited range of intermediate threshold probabilities. Conclusion Tumor bed boost–associated RISI is predictable based on pre-treatment clinico-dosimetric factors. This risk stratification model may assist clinicians in identifying patients at elevated risk before treatment planning and support individualized skin-sparing strategies. As a single-center analysis, the model requires external validation in independent, multi-institutional cohorts before routine clinical use.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: